Enlivex Therapeutics (NASDAQ:ENLV) Reaches New 1-Year Low – Here’s Why

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $0.4277 and last traded at $6.9210, with a volume of 816906 shares changing hands. The stock had previously closed at $7.2075.

Enlivex Therapeutics News Roundup

Here are the key news stories impacting Enlivex Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Enlivex Therapeutics and kept a $300 price objective, while slightly raising earnings estimates for FY2026, FY2027 and several quarterly periods, which can support investor optimism about the company’s longer-term outlook.
• Neutral Sentiment: The analyst revisions suggest Enlivex is still expected to post losses in the coming periods, but the forecast changes were small and mostly incremental rather than a major fundamental re-rating.
• Negative Sentiment: Short interest surged sharply in June, indicating more bearish positioning in the stock and adding pressure to the shares as traders may be betting against near-term performance.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. HC Wainwright upped their target price on shares of Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Friday, June 26th. Finally, Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Enlivex Therapeutics has a consensus rating of “Hold” and a consensus price target of $247.50.

Enlivex Therapeutics Stock Down 7.3%

The company’s 50 day simple moving average is $10.15 and its 200 day simple moving average is $13.18.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in Enlivex Therapeutics by 99.4% in the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares during the last quarter. HRT Financial LP grew its holdings in shares of Enlivex Therapeutics by 719.4% during the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Enlivex Therapeutics by 53.2% during the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after purchasing an additional 45,303 shares during the last quarter. Jane Street Group LLC increased its position in shares of Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares in the last quarter. Finally, XTX Topco Ltd increased its position in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after purchasing an additional 19,132 shares in the last quarter. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.